Omega-3 fatty acids

Generic Name: Omega-3 fatty acids

Brand Names: Animi-3 With Vitamin D, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 329042-31-1

Unique Ingredient Identifier: 71M78END5S

Background: Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that origin...

Indication: Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia.

Associated Conditions: -

Associated Therapies: Nutritional supplementation, Parenteral Nutrition

Clinical Trials

Inositol and Omega-3 Fatty Acids in Pediatric Mania

Phase 4

Completed

Conditions: Pediatric Bipolar Spectrum Disorders

Interventions: Drug: Inositol
Drug: Omega-3

First Posted Date: 2011-07-18

Last Posted Date: 2020-08-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 69

Registration Number: NCT01396486

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Omega-3 Fatty Acids in Tourette's Disorder

Not Applicable

Completed

Conditions: Tourette's Disorder

Interventions: Drug: Olive oil
Drug: Omega-3 Fatty Acids

First Posted Date: 2011-03-15

Last Posted Date: 2014-07-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 33

Registration Number: NCT01315327

Locations: 🇺🇸
NYU Child Study Center, New York, New York, United States

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Phase 2

Terminated

Conditions: Autism Spectrum Disorder (ASD)

Interventions: Drug: Omega-3 Fatty Acid

First Posted Date: 2010-11-25

Last Posted Date: 2024-07-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 7

Registration Number: NCT01248130

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo soybean oil
Drug: OMEGA-3

First Posted Date: 2010-11-05

Last Posted Date: 2022-03-17

Lead Sponsor: Montreal Heart Institute

Target Recruit Count: 337

Registration Number: NCT01235130

Locations: 🇨🇦
Montreal Heart Institute Coordinating Center, Montreal, Quebec, Canada

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

Phase 2

Completed

Conditions: Asthma
Obesity

Interventions: Dietary Supplement: omega-3 polyunsaturated fatty acids
Drug: Omega-3 Fatty Acid

First Posted Date: 2009-12-07

Last Posted Date: 2023-09-08

Lead Sponsor: Nemours Children's Clinic

Target Recruit Count: 143

Registration Number: NCT01027143

Locations: 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Nemours Children's Hospital/Dept of Pulmonology, Orlando, Florida, United States
🇺🇸
University of South Florida, Morsani College of Medicine, Tampa, Florida, United States

Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins

Not Applicable

Completed

Conditions: Inflammation
Blood Pressure
Platelet Function
Endothelial Function

Interventions: Drug: placebo
Drug: omega-3

First Posted Date: 2009-09-15

Last Posted Date: 2010-06-08

Lead Sponsor: Assaf-Harofeh Medical Center

Target Recruit Count: 52

Registration Number: NCT00976872

The Role Of Omega-3 Fatty Acids In Adolescent Depression

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Dietary Supplement: Corn oil
Drug: Omega 3 Fatty Acids

First Posted Date: 2009-08-20

Last Posted Date: 2018-04-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 16

Registration Number: NCT00962598

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

Phase 3

Terminated

Conditions: Heart Disease
Hypertension
Diabetes
Cardiovascular Disease
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases

Interventions: Drug: Placebo
Drug: Omega-3

First Posted Date: 2009-07-09

Last Posted Date: 2014-09-29

Lead Sponsor: Denver Health and Hospital Authority

Target Recruit Count: 76

Registration Number: NCT00935766

Locations: 🇺🇸
Denver Health and Hospital Authority, Denver, Colorado, United States

Efficacy of Fish Oil in Lupus Patients

Phase 4

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Omega-3
Device: flow-mediated dilation of the brachial artery
Other: corn starch

First Posted Date: 2009-01-23

Last Posted Date: 2016-11-18

Lead Sponsor: Michelle Petri M.D.,MPH

Target Recruit Count: 106

Registration Number: NCT00828178

Locations: 🇺🇸
Lupus Center, Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
The Johns Hopkins Lupus Center, Baltimore, Maryland, United States

Omega-3 for Peri- and Postmenopausal Depression

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Omega-3 Fatty Acids

First Posted Date: 2009-01-21

Last Posted Date: 2014-08-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 31

Registration Number: NCT00825994

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy